Agenzia Italiana del Farmaco
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion - Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion:
risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion.
Summary
- There is a risk of medication errors due to the presence on the market of different cabazitaxel presentations:
- Cabazitaxel Accord (20 mg/mL) concentrate for solution for infusion requires a single-step dilution process;
- Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion requires a two-step dilution process.
- Before the final dilution step either in glucose solution or sodium chloride solution for infusion, the concentration of cabazitaxel is:
- 20 mg/ml for Cabazitaxel Accord
- 10 mg/ml for Jevtana
- A mix-up between the products may lead to medication errors resulting in either overdosing with potentially fatal outcome, or underdosing with reduction of therapeutic effect (see background section below).
- Always check carefully which product is being used and the dilution instructions to ensure that the patient receives the correct dose of cabazitaxel.
Published on: 16 June 2021
#AIFA promuove l’ascolto e la trasparenza
Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Oggi si celebra il #WorldAutismAwarenessDay.
🔵 L'Agenzia Italiana del Farmaco sostiene la Giornata...
Vai al post →
Jelena Ivanovic, dirigente medico dell’Ufficio Procedure Europee di #HTA di #AIFA, è stata eletta Co...
Vai al post →
Biosimilari: webinar AIFA su terzo Position Paper
La Commissione Scientifica ed Economica (CSE) di ...
Vai al post →
🎙️ Il Presidente #AIFA intervistato da @presadirettarai sulle false terapie a base di cellule stami...
Vai al post →
💛 28 marzo 2026 – Giornata Mondiale dell’Endometriosi 💛
#AIFA si illumina di giallo per accendere...
Vai al post →
